On February 28, 2018, CanniMed Therapeutics Inc. (TSX: CMED) announced that the company had started fulfilling orders and shipping CanniMed® Topical Cream Kits to registered patients. This new product was a fusion of CanniMed’s medical cannabis oil with Kalaya™ Carrier Base Gel, created by Avaria Health & Beauty Corp. (“Avaria”), one of Canada’s leading experts in the creation of advanced topical creams, gels, lotions and salves.
The company believes that this new product will introduce a “whole new form of delivery for medical cannabis, ideal for patients who do not wish ingest or vaporize and prefer only localized treatment for their condition.” Localized treatment delivers a concentrated dose of the medicinal ingredients to only the affected area meaning the effect is fast-acting and not wasted on unaffected areas. While cannabis infused topical creams are not new, this product uniquely allows the patient to mix in the oil to his or her desired specification, allowing for a customized experience. The oil and cream are packaged separately and a mixing spoon is included.
There is a considerable amount of anecdotal evidence supporting the topical application of medical cannabis, and a growing body of scientific evidence respecting topical application for conditions such as inflammation, neuropathic pain (particularly in patients with Multiple Sclerosis) and allergic skin conditions. A recent study indicates that CB2 receptors may be key in treating the symptoms of rheumatoid arthritis. CanniMed® Topical Cream is suggested to provide relief by binding to a patient’s CB2 receptors.